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As a result of immunological and nucleic-acid screening of plasma donations for transfusion-
transmissible viruses, and the incorporation of viral reduction processes during plasma 
fractionation, coagulation-factor concentrates (CFC) are now judged safe in terms of many 
known infectious agents, including hepatitis B and C viruses, HIV, and human T-cell 
lymphotropic virus. However, emerging pathogens could pose future threats, particularly 
those with blood-borne stages that are resistant to viral-inactivation steps in the 
manufacturing process, such as non-lipid-coated viruses. As outlined in this Review, better 
understanding of infectious diseases allows challenges from newly described agents of 
potential concern in the future to be anticipated, but the processes of zoonotic transmission 
and genetic selection or modification ensure that plasma-derived products will continue to 
be subject to infectious concerns. Manufacturers of plasma-derived CFC have addressed the 
issue of emerging infectious agents by developing recombinant products that limit the need 
for human plasma during production. Such recombinant products have extended the safety 
profile of their predecessors by ensuring that all reagents used for cell culture, purification 
steps, and stabilisation and storage buffers are completely independent of human plasma.  
Emerging pathogens could pose a substantial threat to recipients of therapeutic 
coagulation-factor concentrates (CFC), as shown by the devastating effect of HIV on 
patients who received these agents. The safety of CFC has improved greatly since their 
introduction, and the risk of infectious diseases caused by plasma-derived preparations 
is now very small. However, everyone concerned with haemophilia, including various 
scientific and medical advisory committees, agrees that vigilance must be maintained to 
ensure that new and unpredictable emerging blood-borne pathogens will not again 
compromise the safety of CFC in the future.
1–3 
The risk of transmission of infectious 
agents by a fresh blood component is very different from that for CFC because there 
might not be an effective pathogen inactivation or removal step in the preparation 
process, and the dose of infectious agent could be much higher than in CFC. The 
special danger of contamination of CFC with pathogens is that a single batch could be 
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used to treat, and possibly infect, hundreds of patients, as happened with HIV. The 
pathogens discussed in this review are all potentially transmissible by fresh blood 
products. The susceptibility to individual pathogens in fresh blood products in a 
particular community will depend on the local epidemiology of the infectious agent. By 
contrast, CFC commonly cross continents from site of plasma collection and 
fractionation to use in recipients in a community with little experience of the agent. This 
review focuses on the potential for emerging risks of infectious agents in CFC because 
an essential public-health objective is to prevent epidemics of serious viral infections in 
patients with haemophilia and others who depend exclusively on CFC for their well-
being.  
 
Search strategy and selection criteria 
The references were selected by the authors from their 
knowledge of published work. 
 
The review is a summary of an interdisciplinary forum of clinicians who treat 
haemophilia, infectious-disease specialists, and epidemiologists that was convened at 
Washington University School of Medicine in St Louis, MO, USA, in June, 2004, to 
discuss infectious-disease risk management in patients with haemophilia. The forum 
had the following objectives: to review emerging blood-borne pathogens and their 
potential effects on therapeutic CFC; to discuss clinical issues related to viral infections 
in patients with haemophilia; and to review the safety of CFC in terms of transfusion-
transmissible infections. 
Emergence of new human pathogens 
The National Academy of Sciences defines an emerging infection as one that is newly 
identified, re-emerging, or drug resistant, with an incidence in people that has 
increased within the previous two decades or is threatening to increase in the near 
future.4 The first step of emergence, known as introduction, occurs when a previously 
unknown pathogen comes into contact with a new host population, or when an 
established pathogen changes its normal interaction pattern with its host population in 
some crucial way to increase in prevalence. In the second step, known as adaptation, 
the emerging agent becomes established and disseminates within the host population. 
The factors that contribute to this process are complex; they include microbial 
adaptation, advances in technology and industry, international travel and commerce, 
the breakdown of public-health measures, economic development and increased land 
use, changes in human demographics and behaviour, and war and famine.4   
 
The introduction of a new pathogen into a previously unexposed population typically 
occurs by interspecies, or zoonotic, transmission. For example, genetic analyses have 
suggested that HIV infection was transmitted to human beings from a common 
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subspecies of chimpanzee (Pan troglodytes troglodytes).5 Another well-publicised 
example of zoonotic transmission is severe acute respiratory syndrome, caused by the 
transmission of a new coronavirus to people, initially in southern China and probably 
from small mammals, which are the natural hosts of the severe-acute-respiratory-
syndrome coronavirus.6 After the virus first appeared in human beings, there was an 
explosive short epidemic. Since clinical symptoms preceded the peak of transmission of 
this virus, outbreaks were restricted by quarantine measures in China, Canada, and 
other countries. Many epidemiologists predict similar types of outbreaks in the future 
with emerging viruses. 
 
A less widely known case of zoonotic transmission is of Nipah virus, a henipavirus that 
causes potentially lethal encephalitis. The natural host is the flying fox (fruit bat); cross-
species transmission of the virus to animals occurred in southeast Asia where farmers 
inhabited areas that had been cleared of forests, inadvertently exposing their livestock 
to flying-fox habitats.7,8 In the late 1990s, there were several outbreaks of Nipah-virus 
infection in pigs, with subsequent transmission of the virus to human beings. In 
Malaysia, of 265 people infected during an outbreak of Nipah-virus infection, 105 died, 
a mortality rate of 40%.9 Two other outbreaks of Nipah-virus infection have since 
occurred in Bangladesh.7,8 The mortality rate among infected individuals approached 
70% in the Bangladeshi outbreaks, and in contrast to the Malaysian outbreaks, the 
virus might have been transmitted from one person to another. Hendra virus, a type of 
henipavirus, causes disease in horses and was reported to be transmitted via exposure 
to secretions from an infected racehorse to its trainer. The transmission vector remains 
unknown but could be an arthropod.10 
 
Any new viral pathogen poised to infect human beings must breach the natural barriers 
to zoonotic transmission that exist at the levels of cellular entry and viral expression. 
New emergent viruses might therefore have to acquire genetic mutations before active 
propagation within people is possible. Some RNA viruses have mutation rates as high as 
one nucleotide per 10 000 copied and therefore could be especially likely candidates for 
zoonotic transmission.11 However, the evolution of a potentially large number of 
adaptive mutations that enable productive replication and efficient continuing 
transmission in a new host is rare, which might help to explain the low frequency of 
emerging agents. However, when an emerging pathogen does succeed in adapting to a 
new host species, the outcome can have a worldwide effect. New pathogens are also 
more likely to emerge in conjunction with opportunistic infections in highly 
immunosuppressed individuals, such as those with congenital immune defects, cancer, 
or AIDS.12 Immunosuppression, especially in xenotransplantation settings, might enable 
a poorly adapted virus to replicate and adapt to human beings and act as a bridge to 
subsequent infection of the healthy population.13,14 
 
These issues apply to infectious agents entering a new host population, but any pre-
existing aetiological agent for which the incidence has increased within the previous two 
decades is also defined as an emerging pathogen. In many cases, an increase in 
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incidence reflects a change in the interaction between host and vector, such as that 
caused by extraordinary changes in ecosystems.15 For example, Rift Valley fever was 
the ultimate cause of a cumulative 200,000 deaths after construction of the Aswan Dam 
on the River Nile in Egypt in the 1960s created conditions in which the arthropod vector 
flourished.16 Guanarito arenavirus emerged in Venezuela after forest clearing disrupted 
the local ecology.17 This viral pathogen can be transmitted from rats to human beings, 
in whom it causes haemorrhagic fever and can pose a threat to the blood supply. As 
more people congregate within mega-cities, especially those of less developed countries 
with less advanced hygiene systems, more emerging infectious agents that arise by 
disruption of ecosystems can be expected. 
 
After introduction and adaptation, the final step in pathogen emergence is the 
dissemination of the emerging infectious agent within the host population.  This step 
can occur with an explosive short outbreak, such as that observed for the Ebola virus or 
the coronavirus associated with severe acute respiratory syndrome. Alternatively, the 
agent can propagate and spread via a slower and more insidious mechanism, such as 
that observed with HIV. 
 
 
Panel: Viruses 
 
CPV   Canine parvovirus 
FPLV   Feline panleucopenia virus 
HBV   Hepatitis B virus 
HCV   Hepatitis C virus 
HIV   Human immunodeficiency virus 
HTLV   Human T-cell lymphotropic virus 
JEV   Japanese encephalitis virus 
PCV   Porcine circovirus 
SLE   St Louis encephalitis virus 
TTMV   Torque-tenominivirus 
TTV   Torque-tenovirus 
WNV   West Nile virus 
YFV   Yellow-fever virus 
 
 
 
Potential threats to blood and blood products 
 
Many infectious agents transmissible by blood transfusion are characterised by a long-
lasting and silent carrier state in which the pathogen circulates in the blood without 
causing noticeable symptoms.18 Blood collected during this phase can be highly 
infective, even though the donor has no symptoms. Agents that meet these criteria 
include hepatitis B and C viruses (HBV and HCV), HIV, human T-cell lymphotropic 
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viruses (HTLV) I and II, and West Nile virus (WNV).19 Because there is routine 
screening for these agents, blood and blood products are generally thought to be safe 
from these pathogens. However, many other viruses, for which donated blood is not 
routinely screened, are known to produce a viraemic phase in the infected individual. 
(Viruses for which we use an abbreviated name in this review are listed in the panel.) 
 
Lipid-enveloped viruses 
 
Flaviviruses, which are small, lipid-enveloped, positive-stranded RNA viruses, are a 
subfamily of arthropod-borne viruses (arboviruses) that cycle between insect and 
vertebrate hosts. At least 40 species are associated with human disease, including 
WNV, dengue virus, St Louis encephalitis virus (SLE), yellow-fever virus (YFV), and 
Japanese encephalitis virus (JEV).20,21 Human beings are the primary host for dengue 
virus and YFV only.  Arboviruses have a vast global distribution and show intriguing 
emergence patterns based on ecological changes (figure 1).22 Because flaviviruses are 
widespread and persistent in insect and animal populations and are so far resistant to 
existing treatments, they pose a potential threat to the blood supply. 
 
 
 
 
 
Figure 1:   
Approximate global 
distribution of 
medically  
important viruses in 
the Japanese 
encephalitis 
serogroup of 
flaviviruses.22 
 
 
 
 
 
 
 
West Nile virus 
 
This flavivirus is spread by mosquito vectors. The most important clinical phenotype of 
non-lethal infection is meningoencephalitis.23 The virus first emerged during a 1999 
outbreak in New York City, resulting in 62 confirmed cases and 22 deaths.24–26 During 
2000 and 2001, similar numbers of human cases were noted in the eastern USA, and 
evidence of WNV found in birds, farm animals, and mosquito pools showed that the 
virus had spread over the whole eastern coast and had begun to spread westward. In 
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2003, the US Centers for Disease Control and Prevention reported 9,862 cases of WNV 
infection in 46 states and 264 associated deaths. The numbers were smaller in 2004, 
with 2,470 reported cases in 41 states and 88 associated deaths. Infections have now 
been recorded in some parts of Canada and Mexico.  Currently, 2% to 3% of people in 
certain areas of the USA are seropositive for WNV. The estimated risk, for example, of 
transmission of the virus through transfusion during the 1999 epidemic in New York 
was about 2.0 viraemic donations per 10 000 donors in the borough of Queens.27 The 
risk varied greatly with time and location during 2002, reaching as high as 1.5 in 1000 
donations.18 Of the 2.5 million blood donations screened for WNV from June to 
December, 2003, 0.05% were positive at first screen, and 0.02% were confirmed. 
Interventions to block transmission of WNV are hampered by the fact that 80% of cases 
of infection are subclinical or asymptomatic.  Since WNV is readily inactivated by low 
pH, high temperature, and detergents, it is of less concern with plasma-protein-derived 
CFC, for which these treatments are typically used during manufacturing. 
 
Dengue fever and dengue haemorrhagic fever 
 
Dengue virus is the most common arthropod-transmitted virus in the world and is an 
important issue worldwide for the blood supply.28 Each year, there are 25 million to 100 
million cases of dengue fever and 250,000 cases of dengue haemorrhagic fever 
throughout the world.29 Dengue haemorrhagic fever or dengue shock syndrome has a 
mortality rate of 10–40%, depending on the degree of access to high-quality tertiary-
care facilities. Between 1980 and 1999, the number of cases of dengue virus in the 
Americas increased by 50 times (figure 2).30 The primary mosquito vector for dengue 
virus, Aedes aegypti, was almost eradicated from the USA after the DDT spraying 
campaigns in the late 1950s but the population is now recovering.31 By comparison, in 
Brazil there is an epidemic of dengue fever and dengue haemorrhagic fever, with an 
estimated 500,000 to 1,000,000 cases per year. Other epidemics are occurring in 
Central America, southeast Asia, and parts of Africa and Oceania. Worldwide, an 
estimated 2.5 billion people are at risk.  The infection has a viraemic phase that lasts 3–
5 days, and most cases remain subclinical. Since no screening tests are in place, 
dengue virus might be expected to pose a future concern for the blood supply. 
 
JEV 
 
This virus is another important arbovirus threatening global blood supplies.32–34 It 
causes severe encephalitis, and the mortality among patients admitted to hospital is 
about 33%, with many survivors having long-term neurological sequelae. The heaviest 
concentrations of infections are in southeast Asia and the Indian subcontinent. 20,000–
50,000 cases are reported every year in China alone. 
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Figure 2:  Reported cases of dengue fever in the Americas, 1980-99.30 
Data for 1999 are provisional 
 
 
Non-lipid-enveloped viruses 
 
Viruses without lipid envelopes tend to be less susceptible than lipid-enveloped viruses 
to inactivation methods because they are typically smaller in size and are likely to have 
greater resistance to heat, irradiation, and solvent detergent treatment. Emerging non-
lipid-enveloped viruses could therefore pose the greatest threat to plasma-derived CFC, 
particularly in light of the recent outbreaks of infections with enteroviruses.35 
 
Enteroviruses 
 
These small non-lipid-enveloped viruses form a separate genus within the picornavirus 
family. More than 70 serotypes have been isolated from people, including polioviruses, 
coxsackieviruses, enterocytopathic human orphan viruses, and enteroviruses 68–71. 
The normal site of replication for these viruses is the gastrointestinal tract; infection is 
subclinical or results in a mild disorder in many cases. However, some of these viruses 
can spread through the blood to other parts of the body, including the central nervous 
system. The resulting diseases can be severe, partly depending on the specific 
enterovirus serotype. Enteroviruses that undergo viraemic phases in their life cycle and 
are associated with substantial morbidity (eg, enteroviruses 70 and 71) could be 
particular threats to blood products.36–40 Enterovirus 70 was the causative agent of 
epidemics of acute haemorrhagic conjunctivitis in Africa, Asia, India, and Europe 
between 1969 and 1974. Enterovirus 71 seems to be highly pathogenic and 
neurovirulent and has been associated with epidemics (eg, in Taiwan, Japan, and 
Australia) of various acute diseases, including aseptic meningitis, encephalitis, paralytic 
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poliomyelitis-like disease, hand-foot-and-mouth disease, herpangina, nonspecific febrile 
illness, upper-respiratory-tract infection, enteritis, and viral exanthema.36–38 Enterovirus 
infections can have a transient viraemic phase that precedes symptoms. This feature, in 
combination with their resistance to inactivation, makes them a potential threat to the 
blood and CFC supplies. In a study in Scotland, 0.024% of blood donations showed 
evidence of enterovirus viraemia.41 This proportion predicts about 1,000 enterovirus-
contaminated transfusions per year in the UK. A wide range of viral loads (figure 3) and 
enterovirus serotypes were detected, including enterovirus 71, coxsackieviruses A2, A5, 
A10, A16, B2, B3, B4, and B5, and echoviruses 11, 13, 18, and 30. In the light of the 
numbers of potential infected donations, initiation of screening methods for 
enteroviruses might be prudent to exclude the possibility of blood-transfusion-
associated transmission of potentially pathogenic variants such as enteroviruses 70 and 
71. 
 
 
 
 
 
 
Figure 3: 
Reported viral loads of 
enterovirus types in Scottish 
donor plasma.41 
 
 
 
Circoviruses 
 
These viruses are the smallest known mammalian nonlipid-enveloped viruses (18–28 
nm) and are distributed ubiquitously among human beings and other mammals.42  
Human circoviruses include torque-tenovirus (TTV) and torque-tenominivirus (TTMV), 
two related viruses with highly divergent sequences. Each has a vast number of distinct 
genotypes. Infected people seem to be viraemic with a wide range of genotypes of both 
viruses, and viral loads are constantly high. Importantly for blood products, these 
extremely small and stable non-lipid-enveloped viruses cannot be removed easily by 
nanofiltration and as with other circoviruses important in veterinary medicine, such as 
porcine circovirus (PCV), they are likely to be highly resistant to heat and other viral 
inactivation protocols used in manufacture of blood products. There are no known 
human diseases associated with circoviruses, but some features suggest that caution is 
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warranted. These viruses have been associated with clinical disease in other species; 
infection with PCV2 is the most commercially important disease in pigs today, leading to 
multisystemic wasting syndrome.43 The virus is the cause of 15% of deaths in pigs, and 
it has already jumped species to cattle and sheep. Chicken anaemia virus, an avian 
circovirus, has been transmitted through contaminated manufactured livestock feed, a 
further indication of the resistance to inactivation of these viruses. In human beings, 
transmission of circoviruses to neonates can be associated with upper-respiratory-tract 
infection.44 Since these viruses might maintain their continuously viraemic but 
asymptomatic state in human beings through some immunosuppressive function, there 
is a theoretical concern that they might also suppress the immune response to other 
infectious agents. 
 
Parvoviruses 
 
Interspecies jumping is one of the primary routes by which new emerging pathogens 
enter the human population. The parvovirus feline panleucopenia virus (FPLV) might 
therefore constitute a future threat to people because of its ability to cross mammalian 
barriers. It is a small non-lipid-enveloped virus that typically infects cats, mink, 
raccoons, Arctic foxes, and raccoon dogs. In 1978, a new pathogenic variant emerged 
in dogs and became known as canine parvovirus (CPV),45 which causes hyperthermia, 
vomiting, diarrhoea, leucopenia, dyspnoea, myocarditis, pneumonitis, and in some 
cases, virus-induced encephalitis.46,47 FPLV took about a decade to assume its new host 
range.48,49 One of the first changes that differentiated CPV from FPLV and other animal 
viruses was in the haemagglutinin molecule. Since then, strains of CPV have undergone 
a series of changes, presumably in response to evolutionary selection, which resulted in 
the global distribution of new variants.48 New antigenic variants (CPV2 types, including 
2a, followed by 2b then 2c) have been isolated from cats and dogs in Japan and Brazil, 
which suggests that interspecies transmission, and presumably genetic conversion, 
continues.50–52 Host adaptation of CPV in canines suggests the possibility of similar 
cross-species transmission, followed by adaptation in human beings.52 This potential 
development could be accelerated by the close contact between dogs and people 
throughout the world. Because they are small, resistant, non-lipid-enveloped viruses, 
such emerging parvoviruses could pose a substantial future threat to blood and blood 
products. 
 
Polyomaviruses 
 
Polyomaviruses, a genus of the larger papovavirus family, are small non-lipid-enveloped 
viruses that might also pose a future risk to blood products. Two viruses, both of which 
were isolated in 1971, are of particular interest. JC virus was first isolated from the 
brain of a patient with Hodgkin’s disease who subsequently developed progressive 
multifocal leucoencephalopathy. BK virus was first isolated from a susceptible 
immunosuppressed patient who had recently received a kidney transplant. The main 
site in the body found to harbour these viruses is the kidney. Lymphoid tissues, 
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including bone marrow and spleen, have also been identified as sites of potential viral 
latency.53–55 Both viruses have also been found in brain tumours.56  
 
BK virus causes mild upper-respiratory-tract symptoms, occasional pyrexia, and 
transient cystitis in immunocompetent individuals. In immunocompromised patients, the 
infection is predominantly associated with diseases of the urogenital tract, particularly 
haemorrhagic cystitis.54 Nephropathy associated with BK virus is emerging as an 
important cause of renal dysfunction and loss of transplanted kidneys; the frequency of 
infection with BK virus in transplant recipients is 5%.57,58 Perhaps of greater concern, 
nucleic-acid sequences from the virus have been reported to persist in mononuclear 
cells of healthy blood donors. Thus, of 231 individuals tested in a study in two different 
centres, 29% were positive for BK virus sequences.54 
 
Clinical infection with JC virus is generally found in association with long-term 
immunosuppression and other chronic diseases, including AIDS, lympho-proliferative 
diseases such as Hodgkin’s disease and chronic lymphocytic leukaemia, sarcoidosis, 
tuberculosis, and systemic lupus erythematosus. JC virus causes chronic 
meningoencephalitis and is associated with progressive multifocal leucoencephalopathy, 
a fatal demyelinating disease of the central nervous system. Typically, the course of 
progressive multifocal leucoencephalopathy is gradual, with initial impairment of 
cognitive function, speech, vision, and movement. As it progresses, the pathology 
accelerates, and patients develop more severe disabilities, including dementia, 
paralysis, blindness, then coma, followed by death. The frequency of progressive 
multifocal leucoencephalopathy increased with the AIDS pandemic, but now, with 
effective antiretroviral therapy, HIV-infected patients rarely develop this disorder.51,52 
Shedding of JC virus (and BK virus) in urine is significantly more common in HIV-
infected patients than in non-HIV-infected individuals.59 Progressive multifocal 
leucoencephalopathy is rare in children and young adults and is more common in 
people in their 50s and 60s; this feature suggests that reactivation of latent virus, and 
not primary infection, is the cause of viral disease. 
 
Prions 
 
Prions are self-replicating proteins implicated in transmissible spongiform 
encephalopathies in people and animals. The prion protein in its physiological form, 
PrPc, is a normal membrane constituent. Its function is uncertain, although it might be 
involved in synaptic transmission or copper metabolism. The protein can undergo 
conformational change to a pathological form in which it is protease-resistant (PrPres) 
and it might also have altered glycosylation. This conformational change increases the 
protein’s ability to aggregate. This form is the agent that causes transmissible 
spongiform encephalopathies. 
 
The most worrying manifestation of transmissible spongiform encephalopathies for 
people is variant Creutzfeldt-Jakob disease, which was first recognised in 1996.60 The 
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disease is caused by an infectious prion similar to that which causes bovine spongiform 
encephalopathy and is transmitted by consumption of contaminated tissue from bovine 
sources. The prion that causes variant Creutzfeldt-Jakob disease is found in lymphoid 
tissue, in contrast to cases of the classic disease, and it therefore presents a potential 
risk of infection through blood and plasma-derived blood products.61 
 
 
 
Figure 4: 
Quantification of PrPc 
protein in fractionated 
human blood.62 
 
Several studies have shown that prions can be transmitted through blood. In one study, 
68% of PrPc quantified in normal blood samples was in the plasma compartment, which 
highlights the potential for similar distributions of infectious prion. Leucocyte depletion 
alone might be insufficient to prevent transmission of PrPres (figure 4).62 Furthermore, 
sheep experimentally infected with the infectious prion associated with bovine 
spongiform encephalopathy or scrapie transmitted the encephalopathies to unexposed 
sheep at a rate of 10–20% after whole-blood donations. Finally, two human cases of 
probable transmission of the prion associated with variant Creutzfeldt-Jakob disease by 
blood from donors who subsequently developed the disorder have been reported. In 
the first case, the recipient received a transfusion in 1996, developed a neurological 
disorder in 2002, and died 13 months after the onset of symptoms. At autopsy, 
characteristic spongiform change was seen in the brain.63 The second patient died 5 
years after a blood transfusion from a donor who subsequently developed variant 
Creutzfeldt-Jakob disease. At autopsy, however, PrPres was found in the spleen and 
cervical lymph nodes, but there was no spongiform histological change or PrPres in the 
brain.64 
 
At present, variant Creutzfeldt-Jakob disease from infected blood donors poses mainly a 
theoretical risk to plasma-derived coagulation factors.65 The risk could be less than that 
associated with fresh blood components because the pathogenic prion will be diluted in 
the starting plasma pool and because it is partly excluded by the differential protein 
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fractionation process from the final CFC.66 More highly purified CFC would probably 
carry a lower risk of prion transmission. However, without a reliable diagnostic test for 
prions, some concern about these agents will remain. In September, 2004, serious 
concerns prompted the UK Departments of Health to issue letters to 6000 recipients of 
products manufactured from UK plasma, warning them that there was a possibility of 
transmission of variant Creutzfeldt-Jakob disease. 
 
Public-health response 
 
Regulatory bodies track adverse outcomes from the use of blood products, and public-
health agencies track infectious disease, but surveillance for infectious agents in the 
blood supply is at an early stage and is not always done efficiently. Effective 
surveillance of blood products requires a coordinated effort by regulatory bodies, 
manufacturers, and treaters. Regulatory bodies must mandate effective postmarketing 
surveillance. Manufacturers must use their global reach to identify rare adverse events, 
and treaters must report adverse events as in the system established by UK 
Haemophilia Doctors’ Organisation.  Machine-readable labels such as those with bar 
codes, electronic health-record databases that track clinical outcomes, and consented 
tissue archives such as those of the US Centers for Disease Control and Prevention and 
the Blood Borne Pathogens Surveillance Project of the Association of Hemophilia Centre 
Directors of Canada are key tools for effective and efficient surveillance.67 Table 1 lists 
some of these organisations. 
 
Current clinical topics: viral disease in patients with haemophilia 
 
Individuals with haemophilia and their physicians are particularly concerned about 
emerging blood-borne infectious diseases because the patients are continually exposed 
to blood and blood-derived products. The problems associated with HIV provide an 
example of the dangers faced by these people. HIV contamination of the blood supply 
was first recognised in 1983, although the first US case of HIV infection is now known 
to have occurred in 1975. By 1985, 74% of patients using factor VIII were 
seropositive.68,69 This degree of infection has had a profound effect on mortality among 
haemophilic patients. The median age at death among patients with haemophilia A 
decreased from 57 years before the HIV epidemic to 35 years in 1995, after the 
epidemic had grown to enormous proportions. By comparison, the median lifespan for 
HIV-negative haemophiliacs was 67 years in 1995.70 Similarly, haemophilic patients 
previously have had high rates of infection with HBV and HCV. Virtually all patients 
treated with CFC before 1985 were exposed to HCV.71 In one study of HIV-negative 
adults, 5% had chronic HBV antigenaemia, 71% were seropositive for HBV, and 82% 
were seropositive for HCV.72 25% of the deaths of HIV-infected patients were from liver 
disease in 1997 to 1999.73 
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Region and organisation  
 
Website 
UK 
UK Haemophilia Alliance   
UK Haemophilia Society 
UK Haemophilia Centre Doctors’ Organisation  
National Creutzfeldt-Jakob Disease Surveillance Unit 
    
http://www.haemophiliaalliance.org.uk 
http://www.haemophilia.org.uk 
http://www.ukhcdo.org 
http://www.cjd.ed.ac.uk 
Canada 
Association of Hemophilia Clinic Directors of Canada 
Blood-Borne Pathogens Surveillance Project 
Canadian Hemophilia Society  
Blood-Borne Pathogen Surveillance Network 
http://www.ahcdc.ca/ 
http://www.ahcdc.ca/bbps 
http://www.hemophilia.ca/en/1.1.1.php 
http://www.hc-sc.gc.ca/pphb-dgspsp/hcai-iamss/bpp-
pts/sys_e.html  
 
USA 
US National Hemophilia Foundation   
Regional Centers of  Excellence for Biodefense and 
Emerging Infectious Diseases  
Centers for Disease Control and Prevention  
 
http://www.hemophilia.org 
http://www2.niaid.nih.gov/biodefense/research/rce.htm 
 
http://www.cdc.gov 
International 
World Federation of Hemophilia http://www.wfh.org 
 
Table 1: Public-health resource organizations 
 
These observations highlight an important clinical issue for the treatment of 
haemophilic patients—that infections with several viruses complicate and confuse the 
clinical picture. For example, among HIV-infected individuals, subsequent HBV infection 
produces chronic disease in about 50% of cases, compared with 10% among HIV-
negative patients.74 HIV infection of a patient chronically infected with HBV, however, 
results in a higher degree of HBV replication. Nevertheless, these patients have milder 
liver inflammation and less liver fibrosis than HIV-negative individuals because the 
pathogenesis of chronic HBV infection is governed by immune-mediated mechanisms. 
Treatment of the immunodeficiency in these patients can accelerate liver disease, so 
antiretroviral therapy in patients infected with both HIV and HBV should include at least 
one agent that is active against HBV. 
 
Similar types of interactions have been observed between HIV and HCV.75 HIV infection 
increases the rate of progression to liver cirrhosis and decreases the response to 
interferon-based treatments.76,77 This last effect has complicated treatment 
recommendations for these patients. If the immune system is well preserved (ie, the 
CD4-cell count is high), treatment of the HCV infection first might be prudent. If the 
patient has more advanced HIV disease, however, therapy for HIV should perhaps be 
started before that for HCV. The effect of infection with HCV on HIV progression 
remains uncertain; however, some studies suggest that patients infected with both 
viruses have accelerated progression of HIV disease and a blunted response to 
antiretroviral therapy. 
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Therapeutic CFC: protection from emerging infectious agents 
 
Replacement therapy has formed the cornerstone of haemophilia treatment for longer 
than 100 years.78 At first, whole blood was the source of exogenous coagulation factors. 
As treatment options evolved, whole blood was replaced with increasingly purified 
plasma product fractions, such as fresh-frozen plasma and cryoprecipitate, culminating 
in the high-purity, plasma-derived and recombinant products available now. 
 
Since the available agents are highly effective, the choice of coagulation factor is driven 
primarily by product safety and cost concerns. Ultimately, cost-benefit analyses are 
needed to help physicians treating haemophilia to choose the best therapeutic option 
rationally. There have been no conclusive studies, but any pharmacoeconomic model 
will need to include some key principles. For example, because haemophilic patients 
need repeated infusions throughout their lives, the cumulative risk of transfusion-
transmitted infectious diseases increases over their lifetimes, although currently the 
perceived overall threat is low. Furthermore, haemophilic patients are well informed 
about their disorder, and they might be expected to demand safer products when they 
hear about emerging infections. Given the complexities associated with choice of 
coagulation factor, clinicians and funders must understand the safety properties of the 
two main types of therapeutics, plasma-derived and recombinant coagulation factors. 
 
Plasma-derived coagulation factors 
 
Human plasma-derived CFC were one of the original products used in the treatment of 
haemophilia. Each year, tens of thousands of patients receive plasma-derived 
products.79 However, for longer than three decades, plasma-derived CFC have been 
known to transmit infectious pathogens.80 Human plasma donations are therefore 
routinely screened for known infectious agents by antigen, antibody, and nucleic-acid 
testing procedures.  Compared with whole blood or plasma, CFC have the additional 
safety advantage of undergoing plasma fractionation and are subject to procedures to 
reduce numbers of viruses during manufacture, including chromatographic 
fractionation, nanofiltration, solvent detergent treatment, and heat inactivation. Thus, 
plasma-derived coagulation factors now have a very low risk of transfusion-mediated 
infection with HBV, HCV, HIV, and HTLV I and II. We emphasise, however, that none of 
the current viral reduction steps in the manufacture of concentrates eliminate the risk of 
transmission of nonlipid-coated viruses. Plasma-derived CFC have been widely available 
for 30 years. They are effective at preventing and stopping haemorrhage in most 
patients with haemophilia and have therefore revolutionised the lives of patients. Many 
are able to treat themselves at home. With regular injections in childhood, most bleeds 
can be prevented, allowing children to grow up with normal joints and not, as was 
previously commonplace, crippled with arthritis. 
 
Recombinant coagulation factors 
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The threat from unknown emerging infectious agents has encouraged manufacturers to 
remove dependency on pooled blood plasma entirely from the manufacturing process. 
They have therefore developed methods for expressing human genes for coagulation 
factors within immortalised tissue-culture cells. Subsequent immunoaffinity and column-
chromatographic purification and viral inactivation and removal steps result in highly 
purified therapeutic preparations that are fully active. These processes decrease the 
likelihood of contamination by emerging infectious agents. There is a possibility, 
however, that the cell line could be infected with, and propagate, a pathological prion.81 
The first recombinant factor VIII concentrate was marketed in 1992 for the treatment 
of haemophilia A. Other products followed (table 2). 
 
 
Addition of human or animal proteins to: Concentrate Producing 
Cell 
Line 
Factor VIII molecule 
Cell culture/ 
purification 
Final 
formulation 
Virus removal/ 
inactivation method
First generation 
RecombinateBioclate* CHO Full-length; coexpressed 
with VWF 
Yes Yes Immunoaffinity,  
ion exchange 
Kogenate/Helixate* BHK Full-length Yes Yes Immunoaffinity, 
ion exchange,  
ultrafiltration 
Helixate* 
Second generation 
ReFacto CHO B-domain deleted Yes No Immunoaffinity,  
ion exchange,  
solvent detergent,  
nanofiltration 
Kogenate FS/ 
Helixate FS 
BHK BHK Full-length Yes No Immunoaffinity, 
ion exchange,  
solvent detergent, 
ultrafiltration 
Helixate FS 
Third generation 
Advate CHO Full-length; coexpressed 
with VWF 
No No Immunoaffinity,  
ion exchange,  
solvent detergent 
ReFacto AF† CHO B-domain deleted No No Immunoaffinity,  
ion exchange,  
solvent detergent,  
nanofiltration 
VWF=von Willebrand factor. *No longer commercially available. †Not yet commercially available. 
 
Table 2: Commercial recombinant factor VIII products 
 
The first-generation recombinant concentrates were manufactured from cultures that 
contained animal and human proteins. Human albumin was also added as an excipient 
to the final preparation. In the second generation, protein stabilisers such as albumin 
were replaced with sucrose to eliminate the potential of pathogen transmission. 
Recombinant factor VIIa is also a second-generation product used to treat 
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haemophiliacs who have antibodies to factor VIII and do not respond to factor VIII 
concentrates. 
 
In third-generation concentrates, the factor-VIII transfected cell line is grown in 
medium without addition of any animal or human proteins.2 This approach has greatly 
reduced the risk that could be posed by future emerging pathogens. The only licensed 
recombinant factor IX concentrate, BeneFIX, is also a third-generation concentrate. To 
improve safety in the manufacture of recombinant concentrates, all manufacturing 
processes now include a virus-inactivation process, such as solvent detergent. In 
addition, the monoclonal antibodies used to purify factor VIII from cell cultures are 
made from hybridoma cell lines grown in the absence of added mammalian protein. 
Although recombinant CFC are judged to be at lower risk of transmitting infectious 
agents, concern has been expressed that they might be associated with a higher 
incidence of alloantibody development in response to the transfused factor VIII.82 
Future gene-transfer technologies might allow the preparation of human clotting-factor 
proteins by novel and high-yielding processes that would enable the native protein to 
be expressed. 
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